Quantification of endogenous neurotransmitters and related compounds by liquid chromatography coupled to tandem mass spectrometry

Olesti, Eulàlia; Rodríguez-Morató, José; Gómez-Gómez, Álex; Ramaekers, Johannes G.; Torre, Rafael de la; Pozo, Óscar J.

doi:10.1016/j.talanta.2018.09.034

Cited by 54 publications

(35 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other analytical techniques can be used simultaneously for the detection of biomarkers for epilepsy, like hormonal changes, neurotransmitter, and extra-ocular movements. The concentrations of neurotransmitters and modulators in the extracellular space are of great importance and can only be measured directly by few techniques (antibodies, PET, microelectrode biosensors, mass spectroscopy of tissue sections) [75,87,88,89]. The results from the carbon nanotube-based microelectrode system have better resolution than conventional neurochemical sensing systems, it allows efflux detection of endogenous neurotransmitters and overcomes the limitations of electrophysiological techniques (Figure 4) [75].…”

Section: Nano-bio-sensing Regime Remediationmentioning

confidence: 99%

Biosensors for Epilepsy Management: State-of-Art and Future Aspects

Tiwari

Sharma

Mujawar

et al. 2019

Sensors

View full text Add to dashboard Cite

Epilepsy is a serious neurological disorder which affects every aspect of patients’ life, including added socio-economic burden. Unfortunately, only a few suppressive medicines are available, and a complete cure for the disease has not been found yet. Excluding the effectiveness of available therapies, the timely detection and monitoring of epilepsy are of utmost priority for early remediation and prevention. Inability to detect underlying epileptic signatures at early stage causes serious damage to the central nervous system (CNS) and irreversible detrimental variations in the organ system. Therefore, development of a multi-task solving novel smart biosensing systems is urgently required. The present review highlights advancements in state-of-art biosensing technology investigated for epilepsy diseases diagnostics and progression monitoring or both together. State of art epilepsy biosensors are composed of nano-enabled smart sensing platform integrated with micro/electronics and display. These diagnostics systems provide bio-information needed to understand disease progression and therapy optimization timely. The associated challenges related to the development of an efficient epilepsy biosensor and vision considering future prospects are also discussed in this report. This review will serve as a guide platform to scholars for understanding and planning of future research aiming to develop a smart bio-sensing system to detect and monitor epilepsy for point-of-care (PoC) applications.

show abstract

Section: Nano-bio-sensing Regime Remediationmentioning

confidence: 99%

Biosensors for Epilepsy Management: State-of-Art and Future Aspects

Tiwari

Sharma

Mujawar

et al. 2019

Sensors

View full text Add to dashboard Cite

show abstract

“…While these approaches cover a broad range of compounds allowing identification of a number of different pathways, they lack sensitivity particularly for low abundant metabolites. Up to now, targeted studies considering first results from untargeted analysis are rarely performed but might help to identify more reliable biomarkers as shown in recent studies by Olesti et al They applied targeted metabolome approaches mainly focusing on neurotransmitters to successfully predict the pharmacological profile of NPS (Olesti et al, 2019a,b). Also improvement of statistical methods, commercial or customized software solution including e.g., deep-learning approaches (Asakura et al, 2018; Grapov et al, 2018) will improve marker finding in the future.…”

Section: Current Limitations and Discussionmentioning

confidence: 99%

Metabolomic Strategies in Biomarker Research–New Approach for Indirect Identification of Drug Consumption and Sample Manipulation in Clinical and Forensic Toxicology?

2019

View full text Add to dashboard Cite

Drug of abuse (DOA) consumption is a growing problem worldwide, particularly with increasing numbers of new psychoactive substances (NPS) entering the drug market. Generally, little information on their adverse effects and toxicity are available. The direct detection and identification of NPS is an analytical challenge due to their ephemerality on the drug scene. An approach that does not directly focus on the structural detection of an analyte or its metabolites, would be beneficial for this complex analytical scenario and the development of alternative screening methods could help to provide fast response on suspected NPS consumption. A metabolomics approach might represent such an alternative strategy for the identification of biomarkers for different questions in DOA testing. Metabolomics is the monitoring of changes in small (endogenous) molecules (<1,000 Da) in response to a certain stimulus, e.g., DOA consumption. For this review, a literature search targeting “metabolomics” and different DOAs or NPS was conducted. Thereby, different applications of metabolomic strategies in biomarker research for DOA identification were identified: (a) as an additional tool for metabolism studies bearing the major advantage that particularly a priori unknown or unexpected metabolites can be identified; and (b) for identification of endogenous biomarker or metabolite patterns, e.g., for synthetic cannabinoids or also to indirectly detect urine manipulation attempts by chemical adulteration or replacement with artificial urine samples. The majority of the currently available literature in that field, however, deals with metabolomic studies for DOAs to better assess their acute or chronic effects or to find biomarkers for drug addiction and tolerance. Certain changes in endogenous compounds are detected for all studied DOAs, but often similar compounds/pathways are influenced. When evaluating these studies with regard to possible biomarkers for drug consumption, the observed changes appear, albeit statistically significant, too small to reliably work as biomarker for drug consumption. Further, different drugs were shown to affect the same pathways. In conclusion, metabolomic approaches possess potential for detection of biomarkers indicating drug consumption. More studies, including more sensitive targeted analyses, multi-variant statistical models or deep-learning approaches are needed to fully explore the potential of omics science in DOA testing.

show abstract

“…The development of analytical detectors with high specificity and sensitivity, together with the use of four isotopically labeled internal standards, has enabled the possibility of reducing or avoiding some steps of the sample preparation. Our method bypassed the extraction step (liquid–liquid extraction and/or solid–liquid extraction) prior to sample analysis using a strategy known as dilute‐and‐shoot 27,28 . This method represents an important reduction in consumables, reagents, and labor and overcomes low extraction recoveries.…”

Section: Discussionmentioning

confidence: 99%

Simplified method for the measurement of plasma alkylresorcinols: Biomarkers of whole‐grain intake

Rodríguez-Morató

Jayawardene

Huang

et al. 2020

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

Rationale Consumption of whole grains is negatively associated with cardiovascular disease (CVD) risk but quantification of whole‐grain intake is challenging. Alkylresorcinols (ARs) are biomarkers of whole‐grain intake. Current methods for AR quantification involve a time‐consuming multi‐step separation process that hampers applicability in large‐scale studies. Methods We developed a streamlined method to quantify ARs in human plasma based on protein precipitation and direct injection into an ultra‐high‐performance liquid chromatograph coupled to a quadrupole time‐of‐flight mass spectrometer operating in atmospheric pressure chemical ionization negative ion mode. Results Separation of five major ARs was achieved, with linearity in the 5 to 550 nmol/L range and a lower limit of detection (LOD) of 0.5 nmol/L and quantification (LOQ) of 5 nmol/L. The within‐run and between‐run precision and accuracy were below 15%, and recoveries above 90%. Once validated, the method was applied to measure concentrations of plasma ARs in subjects who participated in a randomized, crossover trial evaluating the effect of carbohydrate type on CVD risk factors. The unrefined carbohydrate diet with the highest fiber content resulted in the highest plasma AR concentration (93 ± 78 nmol/L), and was significantly different (p <0.01) from lower fiber diets (18 ± 26 nmol/L and 19 ± 26 nmol/L, simple and unrefined carbohydrate, respectively). Conclusions This method offers a simplified approach to measure concentrations of plasma ARs as an objective biomarker of whole‐grain intake that can be applied to large‐scale cohort studies.

show abstract

Quantification of endogenous neurotransmitters and related compounds by liquid chromatography coupled to tandem mass spectrometry

Cited by 54 publications

References 36 publications

Biosensors for Epilepsy Management: State-of-Art and Future Aspects

Biosensors for Epilepsy Management: State-of-Art and Future Aspects

Metabolomic Strategies in Biomarker Research–New Approach for Indirect Identification of Drug Consumption and Sample Manipulation in Clinical and Forensic Toxicology?

Simplified method for the measurement of plasma alkylresorcinols: Biomarkers of whole‐grain intake

Contact Info

Product

Resources

About